Gadobutrol (Gadovist®) versus gadofosveset-trisodium (Vasovist®) in MR venography of the peripheral venous vasculature in deep vein thrombosis: is their a need for blood pool contrast agents?
Completed
- Conditions
- 10014523Deep vein thrombosis
- Registration Number
- NL-OMON36357
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
* Age between 18-65 years
* Objectively documented DVT
* Patient scheduled for CE-MRV
* Patient able to undergo CE-MRV twice within one week
* Patient is not scheduled to receive invasive treatment between both examinations
Exclusion Criteria
* Hemodynamic instability
* Known allergy for gadolinium based MR contrast agents
* Contra-indications for MRI
* eGFR < 30 ml/min
* Claustrophobia
* Pregnancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Image quality of our current method using vasovist will be compared with image<br /><br>quality of the new scan sequence, both with Vasovist and Gadovist as contrast<br /><br>agents. Image quality will assessed both subjectively and objectively. For<br /><br>subjective assessment of image quality a 8-point scale is used to determine<br /><br>clinical suitability and influence of image artifacts. Objective assessment of<br /><br>image quality is performed by measuring the signal-to-noise ratio (SNR) and<br /><br>contrast-to-noise ratio (CNR).</p><br>
- Secondary Outcome Measures
Name Time Method <p>Images quality of DSA images will be compared with MRV data using the same<br /><br>method.</p><br>